Company: CLX
Filing Date: 2025-02-03
Form Type: 10-Q
Source: 0000021076-25-000013
Chunk: 96

Company: CLOROX CO /DE/
Filing Date: 2025-02-03
Form: 10-Q
Item: Part I, Item 8
Chunk 96
---
-K for the fiscal year ended June 30, 2024, and the information in “Cautionary Statement” included in this Report.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

In May 2018, the Board of Directors authorized the Company to repurchase up to $2,000 million in shares of common stock on the open market (the 2018 Open-Market Program), which has no expiration date.

In August 1999, the Board of Directors authorized a stock repurchase program to reduce or eliminate dilution upon the issuance of common stock pursuant to the Company’s stock compensation plans (the Evergreen Program). In November 2005, the Board of Directors authorized the extension of the Evergreen Program to reduce or eliminate dilution in connection with issuances of common stock pursuant to the Company’s 2005 Stock Incentive Plan. The Evergreen Program has no expiration date and has no specified limit as to dollar amount and therefore is not included in column [d] below.

The following table sets forth the purchases of the Company’s securities by the Company and any affiliated purchasers within the meaning of Rule 10b-18(a)(3) (17 CFR 240.10b-18(a)(3)) during the second quarter of fiscal year 2025. [a][b][c][d]PeriodTotal Number ofShares Purchased (1)Average Price Paidper Share (2)Total Number ofShares Purchased asPart of PubliclyAnnounced Plans orProgramsMaximum Number (orApproximate DollarValue) of Shares thatMay Yet Be PurchasedUnder the Plans orProgramsOctober 1 to 31, 2024— $— — $993 millionNovember 1 to 30, 2024452,659 165.69 452,659 $993 millionDecember 1 to 31, 2024453,031 165.55 453,031 $993 millionTotal905,690 $165.62 905,690 

(1)All of the shares purchased in November and December 2024 were acquired pursuant to the Company’s Evergreen Program. 

(2)Average price paid per share in the period includes commission.

Item 5. Other Information

On December 9, 2024, Kirsten Marriner, executive vice president - chief people and corporate affairs officer, entered into a trading plan designed to satisfy the affirmative defense of Rule 10b5-1